Fig. 3.

Absolute cell counts at week 2 of infliximab or steroid treatment in early and late disease. The change in cell number between baseline and week 2 was calculated in the late rheumatoid arthritis (RA) group receiving infliximab (n = 11), the early RA–infliximab group (n = 13) and the early RA–steroid group (n = 16). Changes were analysed for (a) CD14^bright monocytes, (b) CD14^dim monocytes, (c) CD16⁺ granulocytes and (d) CD3^-CD56⁺ NK cells. Significant differences from baseline to week 2 of treatment were calculated using Wilcoxon's signed-rank test. P < 0·05 was considered significant and marked with an asterish (*).